Show simple item record

dc.contributor.authorRothschild, Anthony J.
dc.date2022-08-11T08:10:27.000
dc.date.accessioned2022-08-23T17:09:51Z
dc.date.available2022-08-23T17:09:51Z
dc.date.issued1996-06-01
dc.date.submitted2010-05-05
dc.identifier.citationPsychiatr Clin North Am. 1996 Jun;19(2):237-52.
dc.identifier.issn0193-953X (Linking)
dc.identifier.pmid8827188
dc.identifier.urihttp://hdl.handle.net/20.500.14038/45913
dc.description.abstractAs there are no controlled studies on approaches to patients with treatment-resistant psychotic depression many questions remain to be answered. Those that seem worthy of high priority include (1) the efficacy of novel antipsychotic agents (e.g., clozapine, risperidone) for acute and maintenance treatment; (2) the efficacy of newer antidepressant agents such as the SSRIs and nefazodone plus neuroleptic medications; (3) decision trees to delineate the second and third lines of treatment when the first treatment is ineffective; (4) the comparative efficacy of bilateral versus unilateral ECT; (5) the length of time patients should be maintained on medications (which is of particular importance in the case of neuroleptic agents with their potential to cause tardive dyskinesia); (6) the optimal dose of neuroleptic agent for acute treatment; (7) the optimal length of time for medication trials; (8) the use of antidepressant medications during ECT treatments; (9) the importance of the sequence in which TCAs and neuroleptic agents are administered; (10) the delineation of the clinical characteristics of responders to medication versus ECT treatments; and (11) the role of antiglucocorticoid strategies. The answers to these questions would provide clinicians with important tools to treat patients with psychotic depression, an illness that all too frequently can become treatment-resistant.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=8827188&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.psych.theclinics.com/article/S0193-953X%2805%2970286-0/abstract
dc.subjectAffect
dc.subjectAffective Disorders, Psychotic
dc.subjectAntidepressive Agents
dc.subjectAntipsychotic Agents
dc.subjectCarbamazepine
dc.subjectChemotherapy, Adjuvant
dc.subjectDelusions
dc.subjectDepressive Disorder
dc.subjectDrug Resistance
dc.subjectDrug Therapy, Combination
dc.subjectElectroconvulsive Therapy
dc.subjectHallucinations
dc.subjectHydrocortisone
dc.subjectVerapamil
dc.subjectPsychiatry
dc.titleManagement of psychotic, treatment-resistant depression
dc.typeJournal Article
dc.source.journaltitleThe Psychiatric clinics of North America
dc.source.volume19
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/psych_pp/44
dc.identifier.contextkey1299391
html.description.abstract<p>As there are no controlled studies on approaches to patients with treatment-resistant psychotic depression many questions remain to be answered. Those that seem worthy of high priority include (1) the efficacy of novel antipsychotic agents (e.g., clozapine, risperidone) for acute and maintenance treatment; (2) the efficacy of newer antidepressant agents such as the SSRIs and nefazodone plus neuroleptic medications; (3) decision trees to delineate the second and third lines of treatment when the first treatment is ineffective; (4) the comparative efficacy of bilateral versus unilateral ECT; (5) the length of time patients should be maintained on medications (which is of particular importance in the case of neuroleptic agents with their potential to cause tardive dyskinesia); (6) the optimal dose of neuroleptic agent for acute treatment; (7) the optimal length of time for medication trials; (8) the use of antidepressant medications during ECT treatments; (9) the importance of the sequence in which TCAs and neuroleptic agents are administered; (10) the delineation of the clinical characteristics of responders to medication versus ECT treatments; and (11) the role of antiglucocorticoid strategies. The answers to these questions would provide clinicians with important tools to treat patients with psychotic depression, an illness that all too frequently can become treatment-resistant.</p>
dc.identifier.submissionpathpsych_pp/44
dc.contributor.departmentDepartment of Psychiatry
dc.source.pages237-52


This item appears in the following Collection(s)

Show simple item record